InsidersTradesSigma
Total declarations
Company
▲ Purchases (8 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
8
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-27.8%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Rachman Ilya M, Chairman & CEO. Director active across 1 company, notably Immix Biopharma, Inc.. In total, 9 disclosures have been recorded. Breakdown: 8 buys · 0 sell. Total volume traded: €48k. History available since 20 December 2021. The latest transaction was filed on 10 December 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Rachman Ilya M
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations9 total
746 shares@ US$6.679.0% of flowCommon StockSEC:0001493152-25-027109:0
Canonical exit: 10 Mar 2026 (T+90)
2,500 shares@ US$2.029.9% of flowCommon StockSEC:0001493152-25-013919:0
Canonical exit: 16 Dec 2025 (T+90)
2,178 shares@ US$2.29511.2% of flowCommon StockSEC:0001641172-25-015756:0
Canonical exit: 16 Sept 2025 (T+90)
2,600 shares@ US$2.1311.1% of flowCommon StockSEC:0001493152-24-023287:0
Canonical exit: 5 Sept 2024 (T+90)
3,300 shares@ US$1.809112.0% of flowCommon StockSEC:0001493152-24-022653:0
Canonical exit: 2 Sept 2024 (T+90)
218,359 sharesCommon StockSEC:0001493152-24-020778:0
4,300 shares@ US$2.246519.5% of flowCommon StockSEC:0001493152-24-019366:0
Canonical exit: 12 Aug 2024 (T+90)
4,050 shares@ US$1.0198.7% of flowCommon StockSEC:0001493152-22-032557:0
Canonical exit: 12 Feb 2023 (T+90)
2,500 shares@ US$5.000.0021% mcap50.0% of flowCommon StockSEC:0001493152-21-032038:0
Canonical exit: 20 Mar 2022 (T+90)
9 of 9 declarations
About Rachman Ilya M
Ilya M. Rachman is the CEO and Chairman of Immix Biopharma, Inc., a biopharmaceutical company. He oversees the strategic direction of the company and manages its operations. His expertise in the biopharmaceutical sector allows him to lead initiatives aimed at developing new treatments and improving patient outcomes.
